![]() |
|
|
|||||||
|
|
LinkBack | Thread Tools | Display Modes |
|
|||
|
For patients with breast cancer and bone metastases, denosumab delayed skeletal-related side effects five months longer compared to those on zoledronic acid, according to results presented at the 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium, held Dec. 8-12.
|
| Thread Tools | |
| Display Modes | |
|
|